NASDAQ NMS - GLOBAL MARKET · RXRX
+1.81% · +$0.0597 · Vol 24.7M
Market closed · last close 4:00 PM ET · price as of 19:58:41 ET
Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Biotechnology
$3.36
+ Add to watchlist
Card
Relationship Map

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

Score not reportedVeridion does not publish a score-history trend for RXRX until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
NO SCORE SNAPSHOT COVERAGE
AI Analysis
Sovereign

Why is RXRX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for RXRX are being assembled.
About Recursion Pharmaceuticals Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2021
Employees
600
Country
US

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.29
Day high
$3.38
Day low
$3.21
Previous close
$3.30
52W high
$3.38
-0.60% from high
52W low
$3.21
88% of range
Market cap
$1.8B
EPS
$-1.4900
Shares out
530.8M
Volume
24.7M
VWAP
$3.31
Price history computed in-house
SMA 50 Not reported · Not reported
SMA 200 Not reported · Not reported
52W position 88%
Veridion warehouse edge

Warehouse intelligence for RXRX.

Veridion Score
Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Related public evidence

Continue the RXRX research trail.

Relationship mapTrace receipt-backed holders and filings around RXRX.Congress trackerSearch the public STOCK Act disclosure ledger.Thematic mapTechBio & AI Drug DiscoveryMethodologyReview score inputs, coverage rules, and limitations.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

RXRX insider activity

Recursion Pharmaceuticals Inc

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for RXRX.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

RXRX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for RXRX in this window.
Lobbying spend

RXRX lobbying filings, year to date.

Registered lobbying filings matched to Recursion Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for RXRX in this window.
Latest news · RXRX
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for RXRX.
Options
Sovereign unlock shows live options positioning for RXRX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.